Literature DB >> 15266542

Opioid switching to improve pain relief and drug tolerability.

C Quigley1.   

Abstract

BACKGROUND: Patients with cancer, and increasingly chronic non-cancer pain frequently require strong opioids for pain relief. Morphine is the first-line strong opioid of choice for these patients. While most achieve adequate analgesia with morphine, a significant minority either suffer intolerable side-effects, inadequate pain relief, or both. For these patients switching to an alternative opioid is becoming established clinical practice. However, the evidence for the effectiveness of opioid switching does not appear to be established.
OBJECTIVES: The aim of this review was to investigate the usefulness of opioid switching for patients with pain. SEARCH STRATEGY: Randomised trials that assessed opioid rotation, switching, or substitution in adults or children with acute or chronic pain were sought through electronic databases and by handsearching relevant journals. Date of the most recent search: January 2003. SELECTION CRITERIA: The search strategy retrieved no randomised controlled trials, and therefore no studies were available to enable a quantitative synthesis that would assess the effectiveness of the strategy of opioid switching. DATA COLLECTION AND ANALYSIS: Given the lack of RCTs, the review examined all case reports, uncontrolled, and retrospective studies in an attempt to determine the current level of evidence. MAIN
RESULTS: Fifty-two reports were identified, comprising 23 case reports, 15 retrospective studies/audits and 14 prospective uncontrolled studies. The majority of the reports used morphine as first-line opioid and the most frequently used second-line opioid was methadone. All reports, apart from one, concluded that opioid switching is a useful clinical manoeuvre for improving pain control and/or reducing opioid-related side-effects. REVIEWERS'
CONCLUSIONS: For patients with inadequate pain relief and intolerable opioid-related toxicity/adverse effects, a switch to an alternative opioid may be the only option for symptomatic relief. However, the evidence to support the practice of opioid switching is largely anecdotal or based on observational and uncontrolled studies. Randomised trials, including 'N of 1' studies, where a patient acts as their own control, are needed: firstly, to establish the true effectiveness of this clinical practice; secondly, to determine which opioid should be used first-line or second-line; and thirdly, to standardise conversion ratios when switching from one opioid to another.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266542     DOI: 10.1002/14651858.CD004847

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  45 in total

Review 1.  The role of opioids in cancer pain.

Authors:  Columba Quigley
Journal:  BMJ       Date:  2005-10-08

2.  Gaps and junctions between clinical experience and theoretical framework in the use of opioids.

Authors:  Marianne Kloke
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

3.  The drama of cancer pain: when the research abandons patients and reason.

Authors:  L Moja; S Minozzi; A Liberati; R Gusinu; G F Gensini
Journal:  Intern Emerg Med       Date:  2007-10       Impact factor: 3.397

Review 4.  Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem.

Authors:  Kirsten Auret; Stephan A Schug
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Safety and efficacy of transdermal buprenorphine for the relief of cancer pain.

Authors:  Cho Naing; Kyan Aung; Vanessa Racloz; Peng Nam Yeoh
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-07       Impact factor: 4.553

Review 6.  Cognitive effects of opioids.

Authors:  Scott A Strassels
Journal:  Curr Pain Headache Rep       Date:  2008-01

7.  Methadone initiation and rotation in the outpatient setting for patients with cancer pain.

Authors:  Henrique A Parsons; Maxine de la Cruz; Badi El Osta; Zhijun Li; Bianca Calderon; J Lynn Palmer; Eduardo Bruera
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

8.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

9.  Opioids switching with transdermal systems in chronic cancer pain.

Authors:  C Aurilio; M C Pace; V Pota; P Sansone; M Barbarisi; E Grella; M B Passavanti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-07

10.  Substance P and beta-endorphin mediate electro-acupuncture induced analgesia in mouse cancer pain model.

Authors:  Hyo-Jeong Lee; Jae-Ho Lee; Eun-Ok Lee; Hyo-Jung Lee; Kwan-Hyun Kim; Sun-Hyung Kim; Keun-Sung Lee; Hee-Jae Jung; Sung-Hoon Kim
Journal:  J Exp Clin Cancer Res       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.